<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63711">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01844037</url>
  </required_header>
  <id_info>
    <org_study_id>CP1002</org_study_id>
    <nct_id>NCT01844037</nct_id>
  </id_info>
  <brief_title>OneShot Renal Denervation Registry</brief_title>
  <official_title>Renal Denervation Using the OneShot Ablation System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Covidien</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Covidien</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, prospective registry designed to monitor the outcomes of renal
      denervation with the OneShot Device in a real-world patient population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in office systolic blood pressure (SBP) from baseline to 6 months</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute procedural safety, defined as freedom from renal artery dissection or perforation requiring intervention.</measure>
    <time_frame>One Week</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office diastolic blood pressure (DBP)</measure>
    <time_frame>6, 12, 24, and 36 months post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office SBP</measure>
    <time_frame>6, 12, 24, and 36 months post procedure</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hypertension</condition>
  <condition>Heart Failure</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Renal denervation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be treated with the OneShot ablation system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OneShot Ablation System</intervention_name>
    <description>Renal denervation</description>
    <arm_group_label>Renal denervation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is an acceptable candidate for renal denervation based upon the Instructions
             for Use.

          -  Patient is â‰¥ 18 years old.

          -  Patient provided written informed consent.

        Exclusion Criteria:

          -  Patients who are pregnant, nursing, or planning to become pregnant.

          -  Patients who have only one functioning kidney.

          -  Allergy to contrast or known hypersensitivity to device materials

          -  Patients with renal arteries &lt; 4 mm in diameter.

          -  Patients whose life expectancy is less than the planned period of study involvement.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karen Krygier</last_name>
    <email>Karen.krygier@covidien.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital San Raffaele</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 30, 2013</lastchanged_date>
  <firstreceived_date>April 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
